Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Announces Oncomine Clinical Research Grant Program Call for Submissions to Support Research in Immuno-oncology

06/17/2021 | 10:04am EDT

CARLSBAD - Thermo Fisher Scientific today announced that submissions are now open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology.

This grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Through the Oncomine Clinical Research Grant program, Thermo Fisher will award selected independent clinical research teams with financial support worth up to $200,000 in reagents and general funding. The applications will be reviewed and evaluated by independent and internationally recognized experts. Grant proposals are now being accepted through July 16, 2021.

'The goal of immunotherapy is to provide the immune system with tools to recognize and fight cancers,' said Jose Luis Costa, Ph.D., director of medical affairs for clinical next-generation sequencing and oncology at Thermo Fisher. 'To ensure more patients may benefit from revolutionary immunotherapy-based drugs, further investigation is needed to validate predictive biomarkers that can be used to help identify treatment-eligible individuals. Through the Oncomine Grant program, we're proud to provide support for cutting-edge projects to advance this promising area of research and possibly improve cancer patients' overall management.'

Since its launch in 2020, the Oncomine Clinical Research Grant has been awarded to eight projects worldwide, supporting research in areas including fusion genes detection in solid cancer and hemato-oncology. The most recent Oncomine Clinical Research Grant call focused on advancing research in liquid biopsy, for which four proposals were selected for funding. Grant recipients include Stephen Fox, Peter MacCallum Cancer Centre, Australia; Giulia Siravegna, Harvard Medical School/Massachusetts General Hospital Cancer Center, Boston; Beatriz Bellosillo, Hospital del Mar, Spain and Leomar Y. Ballester, The University of Texas Health Science Center at Houston, Houston.

'This grant will allow us to efficiently characterize circulating free tumor DNA (ctDNA) isolated from ascites fluid in gastric cancer patients and compare it with matched peripheral blood ctDN,' said Dr. Giulia Siravegna, research staff, Massachusetts General Hospital Center and instructor in medicine, Harvard Medical School, Department of Medicine. 'The use of ascitic fluid as a source for predictive and prognostic biomarkers is highly innovative and the ability to further our research in this area with the Oncomine Clinical Research Grant will allow for rapid clinical translation and impactful patient results.'

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.


Jessika Parry

Tel: 419-266-4016

Email: mauricio.minotta@thermofisher.com

(C) 2021 Electronic News Publishing, source ENP Newswire

07/30THERMO FISHER SCIENTIFIC : UBS Adjusts Price Target on Thermo Fisher Scientific ..
07/29THERMO FISHER SCIENTIFIC : JPMorgan Adjusts Price Target for Thermo Fisher Scien..
07/29THERMO FISHER SCIENTIFIC : Goldman Sachs Adjusts Price Target for Thermo Fisher ..
07/29THERMO FISHER SCIENTIFIC : BTIG Adjusts Price Target on Thermo Fisher Scientific..
07/29THERMO FISHER SCIENTIFIC : Cowen Adjusts Price Target on Thermo Fisher Scientifi..
07/28PPD : Q2 Results Increase from Year Ago
07/28SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Wednesday
07/28SECTOR UPDATE : Health Care
07/28ETF PREVIEW : ETFs, Futures Slip Lower Prebell as Wall Street Digests Tech Earni..
07/28Equities Signal Stronger Open as US Futures Rise Pre-Bell; Europe Gains, Asia..
More news
Financials (USD)
Sales 2021 36 049 M - -
Net income 2021 7 139 M - -
Net Debt 2021 12 821 M - -
P/E ratio 2021 30,1x
Yield 2021 0,18%
Capitalization 212 B 212 B -
EV / Sales 2021 6,24x
EV / Sales 2022 6,17x
Nbr of Employees 80 000
Free-Float 89,6%
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Last Close Price 540,01 $
Average target price 572,88 $
Spread / Average Target 6,09%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Scott M. Sperling Independent Director
Sector and Competitors